Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
about
The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratioNew oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectivenessClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanReversal of target-specific oral anticoagulantsAnticoagulation drug therapy: a reviewThe new oral anticoagulants and the future of haemostasis laboratory testingNew oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsNon-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused ReviewManagement of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastyA clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?Dabigatran: patient management in specific clinical settings.Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.Reversal of novel oral anticoagulants in patients with major bleeding.A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timeCoagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatranDabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questionsManaging target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents.Interrupting anticoagulation in patients with nonvalvular atrial fibrillation.Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug ConcentrationsDifferential Effects of Dabigatran and Warfarin on Bone Volume and Structure in Rats with Normal Renal FunctionRelationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation.Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants.Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelinesEvaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting.Coagulation assessment with the new generation of oral anticoagulants.The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patientsPractical management of new oral anticoagulants after total hip or total knee arthroplasty.Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old AgentsThe acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery.Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants.Acute management of bleeding in patients on novel oral anticoagulants.Monitoring target specific anticoagulants.Thrombin inhibitors: surgical considerations and pharmacology.Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations.
P2860
Q26776239-9387AE81-7DC0-4B1A-9472-434C27373F9FQ26863548-DAD897F8-319B-423C-918E-859BD09FC6D4Q26864411-7FFF3DB4-9764-4223-8B40-FE0EC33A8B67Q27003866-C4F5DCAE-79DE-4F62-9544-C2C68E9BE361Q27021871-D5C775EE-6898-4075-8B48-33A853CA1E5AQ27022461-5F24F797-E096-4511-8AE8-126C8D6BC800Q28080616-32ADAA04-02B6-4E66-BE3A-B6BE3E9C26AEQ28081918-C530040E-8035-4A6C-98B3-EA12B46875F6Q33556350-CAA2345B-511E-47B4-B041-71024ED05E42Q33804810-03BEF6C4-D161-423D-BFCE-6698DDC57BCFQ33891915-3F216144-53B4-491C-BFE6-6D960677AA19Q34109813-9D06CB21-69CC-463A-960E-A87A7BC94CD2Q34196100-D604CB0B-DB91-4761-86A4-A06BF4D7DDE2Q34206252-3AB5FD84-12E0-4C15-BA3F-9C7379AB6E96Q34326655-E837BBDF-71D0-4056-8B4E-4D18868CBF53Q34571082-3BE375BF-A8CE-437D-A6A3-5B576E762054Q34571099-375F3A0C-9F8F-404D-AFDE-E5C134DAB5CFQ34638063-677C93DA-6616-4429-8B12-765397266069Q34666269-D913514C-0974-401A-A450-615F42553B20Q34667503-17933AE4-D76B-4AB5-8A29-EAD18BBFAB46Q34688742-69E987B2-A442-4FF9-83D3-41AB0EF5A8F5Q35154142-B29FD88E-D722-4C10-B76F-83A0342BE3DBQ35674404-423C2813-8DAB-4DEE-95AE-9A79C246FEADQ35737441-82627DAC-A0D8-4084-B33D-4CB6092141F2Q36013432-7019922B-E89A-45FD-9433-8E2D48783FD6Q36458797-99579489-71E7-44C8-9A56-1A77B1CEC1C6Q36682317-75490A93-05AE-4F0E-B257-26494AAC9FAAQ36875879-E88CA4AB-B1C7-4A5F-B1E5-A05CFFB517ADQ36968781-5D1D6B85-106D-4440-8986-6F7C73E668DBQ37014482-5C431BA5-38B8-46A5-92FB-8F1BFCD272BCQ37338120-5D60775A-8848-4BD7-89D1-A5BE0E96B67AQ37495788-66808E40-F49A-4786-85F1-E0DB6CBD5CE2Q37552621-D3EF5361-F526-4058-9E05-0DBB39D3555BQ37575117-56134903-8E21-464A-8EC0-419E5629A971Q38006688-9BB37D47-D7CD-41F8-8309-72FC0BB0A82AQ38065318-22E199D8-ACB2-4778-8108-95E055E89DC8Q38065699-4D5C541D-0183-4296-94C7-C18DF9B46E02Q38079153-16256DBE-9CC4-48B2-934D-93F2BD270300Q38079287-C31A160B-221B-4F2E-990D-66A94A53F100Q38091327-0272C912-AE86-416C-A35E-F449F8094703
P2860
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Using the HEMOCLOT direct thro ...... concentrations of dabigatran.
@en
Using the HEMOCLOT direct thro ...... concentrations of dabigatran.
@nl
type
label
Using the HEMOCLOT direct thro ...... concentrations of dabigatran.
@en
Using the HEMOCLOT direct thro ...... concentrations of dabigatran.
@nl
prefLabel
Using the HEMOCLOT direct thro ...... concentrations of dabigatran.
@en
Using the HEMOCLOT direct thro ...... concentrations of dabigatran.
@nl
P1476
Using the HEMOCLOT direct thro ...... concentrations of dabigatran.
@en
P2093
Joachim Stangier
Martin Feuring
P304
P356
10.1097/MBC.0B013E32834F1B0C
P577
2012-03-01T00:00:00Z